Edition:
United Kingdom

Zymeworks Inc (ZYME.TO)

ZYME.TO on Toronto Stock Exchange

23.69CAD
8:08pm BST
Change (% chg)

$-3.38 (-12.49%)
Prev Close
$27.07
Open
$24.86
Day's High
$25.43
Day's Low
$23.69
Volume
15,051
Avg. Vol
7,586
52-wk High
$28.88
52-wk Low
$14.34

Latest Key Developments (Source: Significant Developments)

Zymeworks Files Preliminary Prospectus Supplements For Offering Of Common Shares
Tuesday, 18 Jun 2019 

June 18 (Reuters) - Zymeworks Inc ::ZYMEWORKS FILES PRELIMINARY PROSPECTUS SUPPLEMENTS FOR OFFERING OF COMMON SHARES AND PRE-FUNDED WARRANTS.ZYMEWORKS INC - OFFERING IS EXPECTED TO RAISE TOTAL GROSS PROCEEDS OF ABOUT US$150.0 MILLION.ZYMEWORKS - INTENDS TO USE NET PROCEEDS TO ACCELERATE AND EXPAND DEVELOPMENT OF ZW25, ZW49, TO ADVANCE OTHER PRECLINICAL PROGRAMS.  Full Article

Zymeworks Earns Milestone Payment In Merck Collaboration
Wednesday, 29 May 2019 

May 29 (Reuters) - Zymeworks Inc ::ZYMEWORKS EARNS MILESTONE PAYMENT IN MERCK COLLABORATION.ZYMEWORKS - UNDER TERMS, CO GRANTED MERCK WORLDWIDE, ROYALTY-BEARING LICENSE TO RESEARCH, DEVELOP & COMMERCIALIZE CERTAIN BISPECIFIC THERAPEUTIC CANDIDATES.ZYMEWORKS - UNDER TERMS, CO IS ELIGIBLE TO RECEIVE ADDITIONAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS AS WELL AS TIERED ROYALTIES ON PRODUCT SALES.ZYMEWORKS INC - WILL RECEIVE US$2.0 MILLION IN CONNECTION WITH MERCK'S COMPLETION OF A LATE-STAGE PRECLINICAL STUDY FOR A BISPECIFIC ANTIBODY CANDIDATE.  Full Article

Zymeworks Enters Zymelink Antibody-Drug Conjugate Platform Licensing Agreement With Iconic Therapeutics
Tuesday, 14 May 2019 

May 14 (Reuters) - Zymeworks Inc ::ZYMEWORKS ENTERS ITS FIRST ZYMELINK™ ANTIBODY-DRUG CONJUGATE PLATFORM LICENSING AGREEMENT WITH ICONIC THERAPEUTICS.ZYMEWORKS INC - ZYMEWORKS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS, ROYALTIES, AND WORLDWIDE CO-PROMOTION RIGHTS.ZYMEWORKS INC - ZYMEWORKS ENTITLED TO A SHARE OF REVENUES IF ICONIC OUTLICENSES PROGRAM.ZYMEWORKS INC - AGREEMENT ALSO PROVIDES ZYMEWORKS CO-PROMOTION RIGHTS WITH INCREASED ROYALTIES FOR PRODUCTS DEVELOPED USING ADC PROGRAM..ZYMEWORKS - ENTERED LICENSING AGREEMENT GRANTING ICONIC THERAPEUTICS NON-EXCLUSIVE RIGHTS TO CO'S PROPRIETARY ZYMELINK ANTIBODY-DRUG CONJUGATE PLATFORM.  Full Article

Zymeworks Reports 2019 First Quarter Financial Results
Thursday, 2 May 2019 

May 2 (Reuters) - Zymeworks Inc ::ZYMEWORKS REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS.ZYMEWORKS INC - REVENUE FOR THREE MONTHS ENDED MARCH 31, 2019 WAS $11.9 MILLION AS COMPARED TO $0.04 MILLION IN SAME PERIOD OF 2018.ZYMEWORKS INC - AS OF MARCH 31, 2019, HAD $180.3 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS.ZYMEWORKS INC QTRLY LOSS PER SHARE $0.43.  Full Article

Zymeworks Reports 2018 Year-End Financial Results
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Zymeworks Inc ::ZYMEWORKS REPORTS 2018 YEAR-END FINANCIAL RESULTS.ZYMEWORKS INC - QTRLY EARNINGS PER SHARE $0.29.ZYMEWORKS INC - AS OF DECEMBER 31, 2018, HAD $200.2 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS..  Full Article

Zymeworks Announces Pricing Of Public Offering
Thursday, 7 Jun 2018 

June 6 (Reuters) - Zymeworks Inc ::ZYMEWORKS ANNOUNCES PRICING OF PUBLIC OFFERING.ZYMEWORKS INC- PRICING OF ITS PREVIOUSLY- ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,400,000 COMMON SHARES AT A PRICE OF US$15.75 PER COMMON SHARE.  Full Article

Zymeworks Reports Qtrly Net Income Per Common Share $1.29
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Zymeworks Inc ::ZYMEWORKS REPORTS 2017 YEAR-END FINANCIAL RESULTS.ZYMEWORKS INC - QTRLY RESEARCH AND DEVELOPMENTAL COLLABORATIONS REVENUE $50.1 MILLION.ZYMEWORKS INC - QTRLY NET INCOME PER COMMON SHARE $1.29.  Full Article

Zymeworks Adds New Clinical Sites In Canada And U.S. For Ongoing Study
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Zymeworks Inc ::ZYMEWORKS - ADDS NEW CLINICAL SITES IN CANADA AND U.S. FOR ONGOING ADAPTIVE PHASE 1 STUDY OF CO'S LEAD CLINICAL CANDIDATE, ZW25.  Full Article

Zymeworks reports third quarter loss of $0.65 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Zymeworks Inc :Zymeworks reports third quarter 2017 financial results and provides business update.Revenues for three months ended September 30, 2017 were $0.1 million compared to $2.2 million for same period of 2016​.Qtrly ‍loss per share $0.65​.  Full Article

Zymeworks reports second quarter financial results
Tuesday, 8 Aug 2017 

Aug 9 (Reuters) - Zymeworks Inc --:Zymeworks reports second quarter 2017 financial results.Zymeworks Inc says net loss for three months ended June 30, 2017 was $11.0 million.Q2 revenue $1.3 million versus $6.3 million.  Full Article